STOCK TITAN

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focusing on kidney disease, announced its participation in the 2nd Annual HCW Bioconnect Investor Conference in New York on May 20, 2024. CEO John Butler will engage in a fireside chat at 3:00 p.m. ET. The presentation will be available via webcast on Akebia's investor relations website for 30 days post-conference.

Positive
  • Participation in a high-profile investor conference enhances visibility.
  • Presentation by CEO John Butler could bolster investor confidence.
  • Webcast availability for 30 days extends reach to a broader audience.
Negative
  • No new financial or clinical data disclosed during the announcement.
  • Potential dilution risks if no substantial updates are provided at the event.
  • Lack of specific business development updates may disappoint investors looking for concrete progress.

CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the 2nd Annual HCW Bioconnect Investor Conference on Monday, May 20th, 2024 at 3:00 p.m. ET.

The 2nd Annual HCW Bioconnect Investor Conference will take place in New York, NY on May 20, 2024.

A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-2nd-annual-hcw-bioconnect-investor-conference-302144820.html

SOURCE Akebia Therapeutics, Inc.

FAQ

When is Akebia Therapeutics participating in the HCW Bioconnect Investor Conference?

Akebia Therapeutics will participate on May 20, 2024.

What time will Akebia Therapeutics present at the HCW Bioconnect Investor Conference?

Akebia's presentation is scheduled for 3:00 p.m. ET.

How can I access the Akebia Therapeutics presentation at the HCW Bioconnect Investor Conference?

The presentation will be webcasted and available on Akebia's investor relations website for 30 days.

What is the stock symbol for Akebia Therapeutics?

Akebia Therapeutics trades under the stock symbol AKBA.

Where is the 2nd Annual HCW Bioconnect Investor Conference being held?

The conference will be held in New York, NY.

Akebia Therapeutics, Inc.

NASDAQ:AKBA

AKBA Rankings

AKBA Latest News

AKBA Stock Data

232.65M
188.22M
2.47%
26.27%
6.4%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About AKBA

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.